EWF fragment library construction method in covalent inhibitor design and application thereof
By constructing and maintaining a library of 1028 EWFs, the problem of unpredictable activity and selectivity in the design process in covalent inhibitor design is solved, and the accuracy and success rate of drug design is improved, reducing drug development Time and cost, support personalized drug design.
Patent Information
- Application Number
- CN202410960109.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The lack of a systematic Electronic Warhead Fragment (EWF) library in the design of covalent inhibitors in the prior art makes it difficult to predict and optimize drug activity and selectivity during the design process, and there is a risk of toxicity, lack of effective computing tools and database support. , increasing the difficulty and time-consuming of experimental verification.
A library containing 1028 different types of EWFs was constructed. By collecting and analyzing the structural information of known covalent kinase inhibitors, expanding library types, and applying deep conditional conversion neural network SyntaLinker to generate new EWFs to ensure that The library is diverse and innovative, and adopts continuous maintenance and update mechanisms.
Provides a rich library of EWF fragments, which improves the accuracy and success rate of drug design, reduces drug development time and cost, designs covalent inhibitors with high selectivity and strong affinity, and supports personalized drug design. The technical threshold for drug design has been lowered.
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to a method for constructing an EWF fragment library in the design of a covalent inhibitor and an application thereof. Background Art
[0002] In modern pharmaceutical research, the interaction between drug molecules and target proteins is at the core of therapeutic intervention. Traditional drug design methods mainly rely on non-covalent binding mechanisms, which involve non-covalent interactions such as hydrogen bonds, hydrophobic interactions, and van der Waals forces. These non-covalent drug molecules dominate drug discovery because they generally have good bioavailability and low toxicity. However, non-covalent binding may not provide sufficient stability and selectivity in some cases, especially when targeting certain difficult-to-drug targets.
[0003] Covalent inhibitors offer an alternative strategy by interacting with target proteins through the formation of stable covalent bonds. This covalent binding can significantly improve the affinity and selectivity of drug molecules, especially for targets that are difficult to bind to with traditional non-covalent drugs. The key to the design of covalent inhibitors lies in Electrophilic Warhead Fragments (EWFs), which are chemical groups that can form covalent bonds with specific amino acid residues (such as cysteine) in target proteins. However, despite the potential advantages of covalent inhibitors, their application in drug design is still limited, mainly due to the lack of systematic EWF libraries to support the design process.
[0004] The prior art has deficiencies in the design and development of covalent inhibitors. Compared with non-covalent drug design, the design of covalent inhibitors lacks a systematic method and theoretical basis, which makes it difficult to predict and optimize the activity and selectivity of covalent inhibitors during the design process. There is currently no EWF library specifically designed for covalent inhibitors, which limits the options for medicinal chemists in designing new covalent inhibitors. The design of covalent inhibitors needs to take into account the formation and breaking of covalent bonds, which increases the complexity of the design; at the same time, covalent inhibitors may undergo non-specific covalent binding with non-target proteins, increasing the risk of toxicity. Although covalent inhibitors can provide high affinity, they face challenges in selectivity and specificity, especially in complex biological environments. Due to the lack of effective computational tools and database support, experimental verification of the activity and safety of covalent inhibitors becomes more difficult and time-consuming. Therefore, technicians in this field provide a method for constructing an EWF fragment library in covalent inhibitor design and its application to solve the problems raised in the above background technology. Summary of the invention
[0005] 1. Technical issues to be resolved
[0006] In view of the deficiencies of the prior art, the present invention provides a method for constructing an EWF fragment library in the design of covalent inhibitors and its application, which solves the problems existing in the prior art in the design and development of covalent inhibitors.
[0007] (II) Technical solution
[0008] To achieve the above objectives, the present invention is implemented by the following technical scheme: A method for constructing an EWF fragment library in the design of covalent inhibitors, comprising:
[0009] Collecting structural information of known covalent kinase inhibitors: Through a comprehensive collection of known covalent kinase inhibitors CKIs, these data are mainly derived from scientific literature, patents and public databases; the collected CKI structures will be annotated in detail according to the specific regions where they bind to protein targets; these regions include but are not limited to the front region, DFG region, P-loop region and hinge region; through detailed analysis of these structures, we can identify the key Electrophilic Warhead Fragment, referred to as EWF, used to form covalent bonds;
[0010] Annotation based on regional position: The collected CKI structures will be annotated based on the regional position of their targeted cysteine; this step is crucial because it not only helps us understand the spatial distribution of different EWFs, but also helps to reveal the mode of their interaction with target proteins; this detailed information will provide a solid foundation for the subsequent EWF library construction and drug design;
[0011] Expand the types of Electrophilic Warhead Fragment libraries: Based on the annotations, the present invention will expand the types of EWF libraries; this includes extracting information from existing covalent compound databases such as CovalentInDB, especially those covalent inhibitors containing "Michael acceptor" structures; these data will provide an important supplement to the EWF library, increasing the diversity and coverage of the library;
[0012] Application of deep conditional transformation neural network to generate new EWFs: To further enrich the EWF library, this paper adopts an innovative method - deep conditional transformation neural network SyntaLinker; this advanced model can automatically generate new EWF candidates by learning known chemical structures and patterns; in this way, we can create new structures that are difficult to achieve with traditional methods, greatly expanding the potential of the EWF library;
[0013] Construction of Electrophilic Warhead Fragment Library: A library of 1028 different types of EWFs was constructed; this library is not only advantageous in quantity, but also has significant characteristics in diversity and innovation; the construction of this library adopts strict screening criteria to ensure that each EWF fragment has potential application value;
[0014] Maintenance and updating of the Electrophilic Warhead Fragment library: To keep the EWF library cutting-edge and useful, a mechanism for ongoing maintenance and updating of the library is also included; this will involve regular database reviews, addition of new structures, and elimination of obsolete or invalid structures;
[0015] Application Cases and Experimental Validation: A series of application cases will be provided to demonstrate how to use the EWF library to design covalent inhibitors. In addition, experimental validation will be performed to test the activity and selectivity of the designed molecules to ensure their effectiveness in practical applications.
[0016] Preferably, the method of expanding the types of the Electrophilic Warhead Fragment library comprises the following steps:
[0017] S1. In-depth analysis of the target protein, in-depth study of the structure and function of the target protein, including detailed analysis of its active site, identification of new possible nucleophilic sites or new chemical environments of known sites;
[0018] S2. Literature research and patent analysis: research the latest scientific literature, understand the latest extended Electrophilic Warhead Fragment design and application, analyze related patents, and connect the latest progress in the industry with underutilized chemical space;
[0019] S3. Design new Electrophilic Warhead Fragments. Based on the structural and functional analysis of the target protein, design new Electrophilic Warhead Fragments, considering introducing new functional groups or changing the structure of existing functional groups to increase chemical diversity;
[0020] S4. Development of synthetic strategies, development of new synthetic routes to efficiently synthesize new Electrophilic Warhead Fragments, considering the use of green chemistry principles and sustainable chemical methods;
[0021] S5. Bioactivity and selectivity testing: Conduct bioactivity testing on the newly designed Electrophilic Warhead Fragments to evaluate their affinity and selectivity with the target protein, as well as possible toxicity or side effects;
[0022] S6. Data management and analysis: collect and manage the structural and activity data of newly synthesized Electrophilic Warhead Fragments, and use cheminformatics tools to perform data analysis to identify the most promising compounds;
[0023] S7. Library integration and optimization: Integrate the newly synthesized Electrophilic Warhead Fragments into the existing library, optimize the library based on the test results, and remove compounds with poor activity or selectivity;
[0024] S8. Application and validation: Apply the expanded library to new drug discovery projects and validate the activity and application potential of the compounds in the library through virtual screening or high-throughput screening;
[0025] S9. Feedback and iteration: Based on the application results, collect feedback information, conduct iterative design and testing, and continuously optimize the structure and function of the library.
[0026] Preferably, the construction of the Electrophilic Warhead Fragment library comprises the following steps:
[0027] S1. Target identification and analysis: determine the structure and function of the target protein and identify nucleophilic residues that may react with the Electrophilic Warhead Fragment;
[0028] S2. Literature research and existing database analysis, research known Electrophilic Warhead Fragments and their applications in drug design, and analyze existing compound libraries and databases;
[0029] S3. Design of Electrophilic Warhead Fragment: Based on the nucleophilic residue characteristics of the target protein, an Electrophilic Warhead Fragment that can react with it is designed, and the chemical properties of the fragment, such as charge, polarity, and size, are considered to ensure that it can effectively reach the target and react;
[0030] S4. Synthesis and procurement: synthesize the designed Electrophilic Warhead Fragment or purchase existing compounds from commercial suppliers;
[0031] S5. Biological activity test: perform biological activity test on the synthesized or purchased Electrophilic Warhead Fragment to determine its affinity and reactivity with the target protein;
[0032] S6. Data management and analysis: collect and manage the structure, activity and physicochemical property data of all compounds, and use chemical informatics tools to perform data analysis to identify highly active and specific Electrophilic Warhead Fragments;
[0033] S7. Construct a library, integrate the screened active Electrophilic Warhead Fragments into a library, and establish a detailed description for each fragment in the library, including structure, activity data and synthetic route;
[0034] S8. Optimization and iteration: Based on the results of biological activity tests, the fragments in the library are optimized, and iterative design and testing are performed to improve the activity and selectivity of the fragments in the library;
[0035] S9. Application: Apply the constructed Electrophilic Warhead Fragment library to drug discovery projects to find new candidate drug molecules through virtual screening or high-throughput screening methods.
[0036] Preferably, the SyntaLinker model comprises the following steps:
[0037] S1. Research background. The SyntaLinker model was proposed to address the challenges of fragment connection strategy in drug discovery. The fragment connection strategy connects multiple weakly active fragments to maintain the binding mode of these fragments with the target protein unchanged, thereby obtaining good ligand binding efficiency.
[0038] S2. Model training: using a large database of known compounds for training, the model learns the structure and connection rules of these compounds. During the training process, the model will identify the connection patterns between fragments and build a generative model that can generate new compounds.
[0039] S3. Generate new compounds. Based on the given starting molecular fragment structure and the customized linker constraints, the SyntaLinker model can automatically generate a large number of molecules that meet the constraints and have diverse structures. These generated molecules can be further used for drug design and screening.
[0040] S4. Application, the SyntaLinker model can be applied to fragment-based drug design, especially in small drug development companies and scientific research institutions, to design structurally diverse and potentially active lead compounds;
[0041] S5. Optimization and iteration: Based on the biological activity test results of the generated compounds, the model is optimized and iterated to improve the activity and selectivity of the generated compounds;
[0042] S6. Validation and application: Apply the SyntaLinker model to actual drug discovery projects to verify its potential for application in discovering new drug molecules.
[0043] The method for constructing an EWF fragment library in the design of covalent inhibitors according to claims 1 to 4 is applied in chemistry, biology, pharmacology and computational science to target difficult-to-drug targets and treat complex diseases.
[0044] (III) Beneficial effects
[0045] The present invention provides a method for constructing an EWF fragment library in the design of covalent inhibitors and its application. It has the following beneficial effects:
[0046] 1. In the present invention, by providing a rich EWF fragment library, the process of new drug discovery is greatly promoted. This library will become a valuable resource for medicinal chemists and pharmacologists to explore new chemical space, and help identify and develop new molecules with therapeutic potential. Through precise EWF fragment annotation and classification, the technical solution of the present invention allows researchers to select the most suitable EWF according to specific protein targets and binding sites, thereby improving the accuracy and success rate of drug design. At the same time, the entire development process from drug design to preclinical research can be accelerated through the provided EWF library and related tools. Researchers can quickly screen and optimize candidate molecules and reduce the time and cost of drug development.
[0047] 2. In the present invention, covalent inhibitors have high selectivity and strong affinity due to their covalent binding to the target. The technical solution of the present invention helps to design such inhibitors, thereby improving the efficacy of the drug and reducing potential side effects. Through systematic EWF fragment screening, the present invention helps to develop covalent inhibitors with better pharmacokinetic properties, including improved bioavailability, stability and clearance. At the same time, the deep learning tools and EWF library provided reduce the technical threshold for drug design.
[0048] 3. The present invention supports personalized drug design for specific disease targets, helps promote the development of personalized medicine, and provides patients with more accurate and personalized treatment plans. Through the EWF fragments generated by deep learning, the present invention enhances the diversity of drug molecules, helps avoid drug resistance and improves treatment effects. DETAILED DESCRIPTION
[0049] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0050] Embodiment 1:
[0051] The embodiment of the present invention provides a method for constructing an EWF fragment library in the design of a covalent inhibitor, comprising:
[0052] Collecting structural information of known covalent kinase inhibitors: Through a comprehensive collection of known covalent kinase inhibitors CKIs, these data are mainly derived from scientific literature, patents and public databases; the collected CKI structures will be annotated in detail according to the specific regions where they bind to protein targets; these regions include but are not limited to the front region, DFG region, P-loop region and hinge region; through detailed analysis of these structures, we can identify the key Electrophilic Warhead Fragment, referred to as EWF, used to form covalent bonds;
[0053] Annotation based on regional position: The collected CKI structures will be annotated based on the regional position of their targeted cysteine; this step is crucial because it not only helps us understand the spatial distribution of different EWFs, but also helps to reveal the mode of their interaction with target proteins; this detailed information will provide a solid foundation for the subsequent EWF library construction and drug design;
[0054] Expand the types of Electrophilic Warhead Fragment libraries: Based on the annotations, the present invention will expand the types of EWF libraries; this includes extracting information from existing covalent compound databases such as CovalentInDB, especially those covalent inhibitors containing "Michael acceptor" structures; these data will provide an important supplement to the EWF library, increasing the diversity and coverage of the library;
[0055] Application of deep conditional transformation neural network to generate new EWFs: To further enrich the EWF library, this paper adopts an innovative method - deep conditional transformation neural network SyntaLinker; this advanced model can automatically generate new EWF candidates by learning known chemical structures and patterns; in this way, we can create new structures that are difficult to achieve with traditional methods, greatly expanding the potential of the EWF library;
[0056] Construction of Electrophilic Warhead Fragment Library: A library of 1028 different types of EWFs was constructed; this library is not only advantageous in quantity, but also has significant characteristics in diversity and innovation; the construction of this library adopts strict screening criteria to ensure that each EWF fragment has potential application value;
[0057] Maintenance and updating of the Electrophilic Warhead Fragment library: To keep the EWF library cutting-edge and useful, a mechanism for ongoing maintenance and updating of the library is also included; this will involve regular database reviews, addition of new structures, and elimination of obsolete or invalid structures;
[0058] Application Cases and Experimental Validation: A series of application cases will be provided to demonstrate how to use the EWF library to design covalent inhibitors. In addition, experimental validation will be performed to test the activity and selectivity of the designed molecules to ensure their effectiveness in practical applications.
[0059] The steps to extend the Electrophilic Warhead Fragment library include:
[0060] S1. In-depth analysis of the target protein, in-depth study of the structure and function of the target protein, including detailed analysis of its active site, identification of new possible nucleophilic sites or new chemical environments of known sites;
[0061] S2. Literature research and patent analysis: research the latest scientific literature, understand the latest extended Electrophilic Warhead Fragment design and application, analyze related patents, and connect the latest progress in the industry with underutilized chemical space;
[0062] S3. Design new Electrophilic Warhead Fragments. Based on the structural and functional analysis of the target protein, design new Electrophilic Warhead Fragments, considering introducing new functional groups or changing the structure of existing functional groups to increase chemical diversity;
[0063] S4. Development of synthetic strategies, development of new synthetic routes to efficiently synthesize new Electrophilic Warhead Fragments, considering the use of green chemistry principles and sustainable chemical methods;
[0064] S5. Bioactivity and selectivity testing: Conduct bioactivity testing on the newly designed Electrophilic Warhead Fragments to evaluate their affinity and selectivity with the target protein, as well as possible toxicity or side effects;
[0065] S6. Data management and analysis: collect and manage the structural and activity data of newly synthesized Electrophilic Warhead Fragments, and use cheminformatics tools to perform data analysis to identify the most promising compounds;
[0066] S7. Library integration and optimization: Integrate the newly synthesized Electrophilic Warhead Fragments into the existing library, optimize the library based on the test results, and remove compounds with poor activity or selectivity;
[0067] S8. Application and validation: Apply the expanded library to new drug discovery projects and validate the activity and application potential of the compounds in the library through virtual screening or high-throughput screening;
[0068] S9. Feedback and iteration: Based on the application results, collect feedback information, conduct iterative design and testing, and continuously optimize the structure and function of the library.
[0069] Building the Electrophilic Warhead Fragment library consists of the following steps:
[0070] S1. Target identification and analysis: determine the structure and function of the target protein and identify nucleophilic residues that may react with the Electrophilic Warhead Fragment;
[0071] S2. Literature research and existing database analysis, research known Electrophilic Warhead Fragments and their applications in drug design, and analyze existing compound libraries and databases;
[0072] S3. Design of Electrophilic Warhead Fragment: Based on the nucleophilic residue characteristics of the target protein, an Electrophilic Warhead Fragment that can react with it is designed, and the chemical properties of the fragment, such as charge, polarity, and size, are considered to ensure that it can effectively reach the target and react;
[0073] S4. Synthesis and procurement: synthesize the designed Electrophilic Warhead Fragment or purchase existing compounds from commercial suppliers;
[0074] S5. Biological activity test: perform biological activity test on the synthesized or purchased Electrophilic Warhead Fragment to determine its affinity and reactivity with the target protein;
[0075] S6. Data management and analysis: collect and manage the structure, activity and physicochemical property data of all compounds, and use chemical informatics tools to perform data analysis to identify highly active and specific Electrophilic Warhead Fragments;
[0076] S7. Construct a library, integrate the screened active Electrophilic Warhead Fragments into a library, and establish a detailed description for each fragment in the library, including structure, activity data and synthetic route;
[0077] S8. Optimization and iteration: Based on the results of biological activity tests, the fragments in the library are optimized, and iterative design and testing are performed to improve the activity and selectivity of the fragments in the library;
[0078] S9. Application: Apply the constructed Electrophilic Warhead Fragment library to drug discovery projects to find new candidate drug molecules through virtual screening or high-throughput screening methods.
[0079] The SyntaLinker model consists of the following steps:
[0080] S1. Research background. The SyntaLinker model was proposed to address the challenges of fragment connection strategy in drug discovery. The fragment connection strategy connects multiple weakly active fragments to maintain the binding mode of these fragments with the target protein unchanged, thereby obtaining good ligand binding efficiency.
[0081] S2. Model training: using a large database of known compounds for training, the model learns the structure and connection rules of these compounds. During the training process, the model will identify the connection patterns between fragments and build a generative model that can generate new compounds.
[0082] S3. Generate new compounds. Based on the given starting molecular fragment structure and the customized linker constraints, the SyntaLinker model can automatically generate a large number of molecules that meet the constraints and have diverse structures. These generated molecules can be further used for drug design and screening.
[0083] S4. Application, the SyntaLinker model can be applied to fragment-based drug design, especially in small drug development companies and scientific research institutions, to design structurally diverse and potentially active lead compounds;
[0084] S5. Optimization and iteration: Based on the biological activity test results of the generated compounds, the model is optimized and iterated to improve the activity and selectivity of the generated compounds;
[0085] S6. Validation and application: Apply the SyntaLinker model to actual drug discovery projects to verify its potential for application in discovering new drug molecules.
[0086] The method for constructing an EWF fragment library in the design of covalent inhibitors according to claims 1 to 4 is applied in chemistry, biology, pharmacology and computational science to target difficult-to-drug targets and treat complex diseases.
[0087] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. EWF fragment library construction method for covalent inhibitor design, Features: include: Collecting structural information of known covalent kinase inhibitors: Through a comprehensive collection of known covalent kinase inhibitors (CKIs), these data are mainly derived from scientific literature, patents and public databases; the collected CKI structures will be annotated in detail according to the specific regions where they bind to protein targets; these regions include but are not limited to the front region, DFG region, P-loop region and hinge region; through detailed analysis of these structures, we can identify the key Electrophilic Warhead Fragment (EWF) used to form covalent bonds; Annotation based on regional position: The collected CKI structures will be annotated based on the regional position of their targeted cysteine; this step is crucial because it not only helps us understand the spatial distribution of different EWFs, but also helps to reveal the mode of their interaction with target proteins; this detailed information will provide a solid foundation for the subsequent EWF library construction and drug design; Expand the types of Electrophilic Warhead Fragment libraries: Based on the annotations, the present invention will expand the types of EWF libraries; this includes extracting information from existing covalent compound databases such as CovalentInDB, especially those covalent inhibitors containing "Michael acceptor" structures; these data will provide an important supplement to the EWF library, increasing the diversity and coverage of the library; Application of Deep Conditional Transformation Neural Network to Generate New EWFs: To further enrich the EWF library, this paper adopts an innovative approach - Deep Conditional Transformation Neural Network (SyntaLinker); this advanced model can automatically generate new EWF candidates by learning known chemical structures and patterns; In this way, we are able to create new structures that are difficult to achieve with traditional methods, greatly expanding the potential of the EWF library; Construction of Electrophilic Warhead Fragment Library: A library of 1028 different types of EWFs was constructed; this library is not only advantageous in quantity, but also has significant characteristics in diversity and innovation; the construction of this library adopts strict screening criteria to ensure that each EWF fragment has potential application value; Maintaining and updating the Electrophi l ic Warhead Fragment library: In order to keep the EWF library cutting-edge and useful, a mechanism for ongoing maintenance and updating of the library is also included; this will involve regular database reviews, the addition of new structures, and the elimination of obsolete or invalid structures; Application Cases and Experimental Validation: A series of application cases will be provided to demonstrate how to use the EWF library to design covalent inhibitors. In addition, experimental validation will be performed to test the activity and selectivity of the designed molecules to ensure their effectiveness in practical applications.
2. The method for constructing an EWF fragment library in the design of a covalent inhibitor according to claim 1, Features: The method of extending the type of Electrophi l ic Warhead Fragment library includes the following steps: S1. In-depth analysis of the target protein, in-depth study of the structure and function of the target protein, including detailed analysis of its active site, identification of new possible nucleophilic sites or new chemical environments of known sites; S2. Literature research and patent analysis: research the latest scientific literature, understand the latest extended Electrophilic Warhead Fragment design and application, analyze related patents, and connect the latest progress in the industry with underutilized chemical space; S3. Design new Electrophi l ic Warhead Fragments. Based on the structural and functional analysis of the target protein, design new Electrophi l ic Warhead Fragments, considering introducing new functional groups or changing the structure of existing functional groups to increase chemical diversity; S4. Development of synthetic strategies, development of new synthetic routes to efficiently synthesize new Electrophilic Warhead Fragments, considering the use of green chemistry principles and sustainable chemical methods; S5. Bioactivity and selectivity testing: Conduct bioactivity testing on the newly designed Electrophilic Warhead Fragments to evaluate their affinity and selectivity with the target protein, as well as possible toxicity or side effects; S6. Data management and analysis: collect and manage the structural and activity data of newly synthesized Electrophilic Warhead Fragments, and use cheminformatics tools to perform data analysis to identify the most promising compounds; S7. Library integration and optimization: Integrate the newly synthesized Electrophilic Warhead Fragments into the existing library, optimize the library based on the test results, and remove compounds with poor activity or selectivity; S8. Application and validation: Apply the expanded library to new drug discovery projects and validate the activity and application potential of the compounds in the library through virtual screening or high-throughput screening; S9. Feedback and iteration: Based on the application results, collect feedback information, conduct iterative design and testing, and continuously optimize the structure and function of the library.
3. The method for constructing an EWF fragment library in the design of a covalent inhibitor according to claim 1, Features: The construction of the Electrophi l ic Warhead Fragment library includes the following steps: S1. Target identification and analysis: determine the structure and function of the target protein and identify nucleophilic residues that may react with the Electrophilic Warhead Fragment; S2. Literature research and existing database analysis, research known Electrophilic Warhead Fragments and their applications in drug design, and analyze existing compound libraries and databases; S3. Design an Electrophi l ic Warhead Fragment, based on the nucleophilic residue characteristics of the target protein, involving an Electrophi l ic Warhead Fragment that can react with it, considering the chemical properties of the fragment, such as charge, polarity and size, to ensure that it can effectively reach the target and react; S4. Synthesis and procurement: synthesize the designed Electrophi l ic Warhead Fragment or purchase existing compounds from commercial suppliers; S5. Biological activity test: perform biological activity test on the synthesized or purchased Electrophi l ic Warhead Fragment to determine its affinity and reactivity with the target protein; S6. Data management and analysis: collect and manage the structural, activity and physicochemical property data of all compounds, and use chemical informatics tools to perform data analysis to identify highly active and specific Electrophi l ic Warhead Fragments; S7. Construct a library, integrate the screened active Electrophi l ic Warhead Fragments into a library, and establish a detailed description for each fragment in the library, including structure, activity data and synthesis route; S8. Optimization and iteration: Based on the results of biological activity tests, the fragments in the library are optimized, and iterative design and testing are performed to improve the activity and selectivity of the fragments in the library; S9. Application: Apply the constructed Electrophi l ic Warhead Fragment library to drug discovery projects to search for new candidate drug molecules through virtual screening or high-throughput screening methods.
4. The method for constructing an EWF fragment library in the design of a covalent inhibitor according to claim 1, Features: The SyntaLinker model includes the following steps: S1. Research background. The SyntaLinker model was proposed to address the challenges of fragment connection strategy in drug discovery. The fragment connection strategy connects multiple weakly active fragments to maintain the binding mode of these fragments with the target protein unchanged, thereby obtaining good ligand binding efficiency. S2. Model training: using a large database of known compounds for training, the model learns the structure and connection rules of these compounds. During the training process, the model will identify the connection patterns between fragments and build a generative model that can generate new compounds. S3. Generate new compounds. Based on the given starting molecular fragment structure and the customized linker constraints, the SyntaLinker model can automatically generate a large number of molecules that meet the constraints and have diverse structures. These generated molecules can be further used for drug design and screening. S4. Application, the SyntaLinker model can be applied to fragment-based drug design, especially in small drug development companies and scientific research institutions, to design structurally diverse and potentially active lead compounds; S5. Optimization and iteration: Based on the biological activity test results of the generated compounds, the model is optimized and iterated to improve the activity and selectivity of the generated compounds; S6. Validation and application: Apply the SyntaLinker model to actual drug discovery projects to verify its potential for application in discovering new drug molecules.
5. The method for constructing an EWF fragment library in the design of covalent inhibitors according to claims 1 to 4, Features: With applications in chemistry, biology, pharmacology, and computational science, targeting hard-to-druggable targets and treating complex diseases.
Citation Information
Patent Citations
Compound optimization method based on deep learning connection fragment
CN114187978A
Construction method and application of covalent molecular fragment library for designing and developing targeted covalent inhibitor
CN117230534A
